Treating a cloth baby wrap with permethrin cut childhood malaria by two thirds

Malaria control has spent two decades optimising a single intervention delivered at a single time of day. Insecticide-treated bed nets work while people are in bed. A trial published in the New England Journal of Medicine on 24 September tested protection for the rest of the day, using an object that was already there: the cloth wrap in which mothers carry babies on their backs [s1].

Treating those wraps with permethrin reduced clinical malaria in the children by roughly two thirds, in a population where every family also received a new bed net [s1].

The trial

The study was double-blind, randomised and placebo-controlled, conducted in Uganda [s1]. It enrolled adult women with a child aged 6 to 18 months and assigned the mother-child pairs 1:1 to permethrin-treated wraps or sham-treated wraps [s1]. Wraps were retreated every four weeks [s1].

Critically, all participants — both groups — received a new pyrethroid-only long-lasting insecticide-treated bed net [s1]. The comparison is therefore not "wrap versus nothing" but "wrap plus net versus net alone," which is the question a malaria programme actually faces.

From June 2022 through April 2024, 419 mother-child pairs were screened and 400 randomised, 200 to each group [s1]. Participants visited trial clinics every two weeks for 24 weeks, with unscheduled visits for febrile illness [s1]. The primary outcome was clinical malaria in the children, defined as fever plus a positive rapid diagnostic test [s1].

Follow-up was close to complete: 5,194 of 5,200 planned visits were attended (99.9%), and no participants were lost to follow-up [s1]. In a trial of this size, that matters as much as the effect estimate — differential dropout is the usual way an apparent malaria benefit turns out to be an artefact.

The result

Clinical malaria incidence was 0.73 cases per 100 person-weeks (95% CI, 0.51 to 1.02) in the intervention group and 2.14 per 100 person-weeks (95% CI, 1.73 to 2.62) in the control group [s1]. The incidence rate ratio was 0.34 (95% CI, 0.23 to 0.51; P<0.001) [s1].

Rash was reported more often in the intervention group than in the control group, in 8.5% versus 6.0% of participants [s1].

Where this sits in the vector-control literature

A systematic review and meta-analysis published in August pooled the entomological evidence on volatile pyrethroid spatial repellents — a related but distinct approach, in which a pyrethroid evaporates into the air rather than sitting on fabric in contact with skin [s2]. Across 58 eligible publications, spatial repellents provided an average of 56% protective efficacy against mosquito bites (95% CI, 50 to 62) [s2]. Meta-analysis of individual mosquito-level data from 50 of those studies, covering 1,703,120 mosquitoes, found similar protection in semi-field (58%; 95% CI, 54 to 62) and field studies (50%; 95% CI, 40 to 59) [s2].

Two findings in that review bear directly on how far the wrap result should be extrapolated. Species-level differences were observed, with low protective efficacy against Anopheles funestus (31%; 95% CI, 19 to 43) — a major African malaria vector [s2]. And the review notes that the potential for cross-resistance to solid-state pyrethroids is unclear [s2].

Both points cut against assuming the Uganda result transfers. The wrap trial was conducted in one country with one vector population and one resistance profile. Pyrethroid resistance is widespread across sub-Saharan Africa, and the trial's own bed nets were pyrethroid-only rather than the newer dual-active-ingredient nets deployed where resistance is high [s1]. The reviewers of the spatial-repellent literature call explicitly for more field studies evaluating outdoor protection in malaria-endemic settings, particularly in West Africa, South America and Southeast Asia [s2].

What the trial does not settle

The trial measured clinical malaria over 24 weeks in children aged 6 to 18 months at enrolment [s1]. It does not report severe malaria, anaemia or mortality, and was not sized for them.

It does not establish the mechanism. A permethrin-treated wrap could work by repelling mosquitoes, by killing those that land, or by reducing biting on the mother and therefore local transmission — and the trial's design does not separate these.

Nor does it address durability or logistics. Retreatment every four weeks was performed within a trial [s1]; whether households sustain a four-weekly retreatment schedule outside one is unknown, and a wrap that is washed, worn out or replaced without retreatment is just a cloth.

The rash imbalance is small and the trial was not powered to characterise it, but permethrin on fabric held in continuous contact with an infant's skin is a dermal exposure question that longer and larger studies would need to address.

The trial was funded by the Doris Duke Foundation and others, and registered as NCT05391230 [s1].

What to watch: replication in a different vector and resistance setting, and whether any programme attempts wrap treatment at scale.

This article is informational and is not medical advice.

Sources

• [s1] "Permethrin-Treated Baby Wraps for the Prevention of Malaria," New England Journal of Medicine, published online 24 September 2025. https://doi.org/10.1056/NEJMoa2501628
• [s2] "Volatile pyrethroid spatial repellents for preventing mosquito bites: a systematic review and meta-analysis," EBioMedicine, 26 August 2025. https://doi.org/10.1016/j.ebiom.2025.105891